CytoMed Therapeutics
GDTC
GDTC
2 hedge funds and large institutions have $21.5K invested in CytoMed Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
UBS Group
Zurich,
Switzerland
|
+$14.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.32K |
Top Sellers
| 1 |
SSG
Summit Securities Group
New York
|
-$19K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
UBS Group
Zurich,
Switzerland
| $17.2K | +$14.8K | +3,023 | +634% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $4.32K | +$4.32K | +882 | New |
|
|
SSG
3
Summit Securities Group
New York
| – | -$19K | -5,407 | Closed |
|